Latest Breaking News On - John fraunces - Page 6 : comparemela.com

Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering

Tenax Therapeutics Announces Pricing of Approximately $9

CHAPEL HILL, N.C., Feb. 08, 2024 (GLOBE NEWSWIRE) Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying,.

Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - Tenax Therapeutics (NASDAQ:TENX)

Once granted, this patent will: provide U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond 2040broaden IP protection for oral

EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements

Company reports preliminary placement results of twelve Focal One Systems, inclusive of ten capital salesLYON, France, January 8, 2024 - EDAP TMS .

EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements -January 08, 2024 at 08:01 am EST

Company reports preliminary placement results of twelve Focal One Systems, inclusive of ten capital sales LYON, France, January 8, 2024 - EDAP TMS SA , , the global leader in robotic energy-based.